Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
January 30, 2018
Assignee:
ONCOIMMUNE, INC.
Inventors:
Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
Abstract: A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.
Type:
Grant
Filed:
July 13, 2015
Date of Patent:
January 9, 2018
Assignee:
THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS
Abstract: The present invention relates to the use of epidermal growth factor receptor (EGFR) antagonists in methods and compositions useful for the treatment of heart disease in a subject. In one embodiment, the methods of the present invention comprise: (a) administering to the subject an EGFR antagonist; and (b) inhibiting or substantially inhibiting the EGFR signal transduction cascade. In another embodiment the method of the present invention may be used in combination with another heart disease therapy.
Abstract: Topical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
January 2, 2018
Assignee:
PROMIUS PHARMA LLC
Inventors:
Sateesh Kandavilli, Madhusudhan Bommagani, Vijendra Nalamothu, Franklin Okumu
Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
December 26, 2017
Assignee:
North Carolina Agricultural and Technical State University
Abstract: This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.
Abstract: The present invention relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least glyceryl caprylate, 1,3-propanediol and phytic acid or any of the salts thereof, said composition being free from perlite. The present invention further relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least glyceryl caprylate, 1,3-propanediol and phytic acid or any of the salts thereof.
Abstract: Injectable bone graft material having a biocompatible, resorbable polymer and a biocompatible, resorbable inorganic material exhibiting macro, meso, and microporosities.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
October 17, 2017
Assignee:
Orthovita, Inc.
Inventors:
Charanpreet S. Bagga, Theodore D. Clineff, Erik M. Erbe, Michael W. Paris, Gina M. Nagvajara, Antony Koblish
Abstract: A composition comprising: a benefit agent; at least one polymer including a polycaprolactone polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent is disclosed.
Type:
Grant
Filed:
November 8, 2016
Date of Patent:
October 10, 2017
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Ying Sun, Anna Gosiewska, Dennis D. Jamiolkowski, Jeffrey M. Wu
Abstract: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.
Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
Abstract: The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.
Abstract: The present invention relates to compounds and methods for treating viral diseases. Some compounds of the invention are described by Formula I: wherein M+ is Na+, Li+, K+, Ca2+, Mg2+, or NRcRdReRf+ and Rc, Rd, Re and Rf are each independently hydrogen or C1-5 alkyl, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.
Type:
Grant
Filed:
March 30, 2015
Date of Patent:
September 19, 2017
Assignee:
Chimerix, Inc.
Inventors:
Merrick Almond, Bernhard Lampert, Ernest Randall Lanier, Roy W. Ware
Abstract: Provided according to some embodiments of the invention are methods of manufacturing a pharmaceutical composition. In some embodiments, such methods include homogenizing at a first excipient composition that includes a viscosity agent and at least one solvent to form a first premix composition; separately homogenizing at least one active pharmaceutical ingredient (API) and a second excipient composition to form a second premix composition; and combining the first premix composition and the second premix composition to form the composition. The pre-mixing of constituents may increase the stability of the API and provide uniformity of the dispersion of the constituents throughout the final topical composition.
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Type:
Grant
Filed:
December 5, 2014
Date of Patent:
August 29, 2017
Assignee:
Rempex Pharmaceuticals, Inc.
Inventors:
David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
Type:
Grant
Filed:
October 15, 2015
Date of Patent:
August 29, 2017
Assignee:
North Carolina Agricultural and Technical State University
Abstract: Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.